Clinical trials: Cardiac Toxicity, active
Heart Failure
Heart Failure in Women: Epidemiological and Prognostic Insights
Heart failure (HF) is a leading cause of hospital admission in older adults and women account for more than half of these admissions, yet they remain under-represented in prospective HF cohorts.
- Trial name
- HER-HF (NCT07847983)
- Where
- 24 sites in Spain
- Volunteers
- 430 people
- Sponsor
- Carolina Ortiz Cortes
Cardiotoxicity
Cardioprotection Effect of Linagliptin
1. Background and Rationale Breast cancer is one of the most common malignancies affecting women worldwide and represents a major health burden in Egypt.
- Trial name
- Linagliptin (NCT07852546)
- Testing
- Doxorubicin, Empaglifloz 5 mg orally once daily
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Tanta University
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
- Trial name
- START (NCT06214195)
- Testing
- Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Zhejiang Cancer Hospital
Anthracycline Related Cardiotoxicity in Childhood Cancers, Chemotherapeutic Toxicity
Evaluation of Cardiac and Endothelial Function in Children and Adolescents Treated With Anthracycline
In recent decades, the survival rate of children with cancer has increased significantly thanks to personalized treatments and the adoption of international therapeutic protocols.
- Conditions
- Anthracycline Related Cardiotoxicity in Childhood Cancers, Chemotherapeutic Toxicity, Childhood Cancer Survivors
- Trial name
- CARDIO-PED (NCT07253077)
- Testing
- Biomarker detection
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Neoplasms
Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy
The goal of the HARMONIC-RT study is to evaluate late health and social outcomes of contemporary techniques of external beam radiotherapy in paediatric patients, based on the setting-up of a European, long-term registry…
- Trial name
- HARMONIC-RT (NCT04746729)
- Testing
- No intervention
- Where
- 5 sites in Belgium, Denmark and 2 more
- Volunteers
- 2,670 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Breast Cancer, Heart Failure
CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.
- Trial name
- PROTECTAA (NCT06304857)
- Testing
- Dapagliflozin
- Where
- 3 sites in Poland
- Volunteers
- 188 people
- Sponsor
- 4th Military Clinical Hospital with Polyclinic, Poland
Heart Failure, Cardiotoxicity
The STOP-MED CTRCD Trial
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients.
- Conditions
- Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity
- Trial name
- STOP-MED CTRCD (NCT06183437)
- Testing
- Stopping Heart Failure Medication(s)
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 335 people
- Sponsor
- Dinesh Thavendiranathan
Breast Cancer
Cardiotoxicity of Cancer Therapy (CCT)
The objective of this study is to define the clinical significance of mechanistic biomarkers (including Neuregulin-1Beta) and novel echocardiographic measures of cardiac function in predicting the incident risk of cancer therapy…
- Trial name
- NCT01173341
- Testing
- Echocardiography, Blood Collection, Symptoms Questionnaire
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer, Cardiotoxicity
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
This is an observational study for patients with breast cancer that will be treated with doxorubicin (Adriamycin) and/or trastuzumab (Herceptin).
- Conditions
- Breast Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases
- Trial name
- CCT2 (NCT05078190)
- Testing
- Social Determinants of Health
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Empgliflozin Cardioprotective Effect
Cardioprotective Effect of Empagliflozin in Breast Cancer Patients
Background: Doxorubicin (DOX) remains a cornerstone in adjuvant and neoadjuvant therapy for breast cancer, but its utility is hindered by dose-dependent cardiotoxicity.
- Trial name
- NCT07815808
- Testing
- Empagliflozin (EMPA), Metformin
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Tanta University
Lymphoma, Physical Exercise
Effects of Exercise Training in Survivors of Lymphoma
This study aims to compare the effects of aerobic exercise with or without addition of resistance exercise to usual care in individuals treated with anthracyclines for lymphomas and to compare exercise effects to age- and…
- Conditions
- Lymphoma, Physical Exercise, Cardiotoxicity, Cardiovascular Diseases
- Trial name
- LYMfit (NCT06270667)
- Testing
- Aerobic Exercise, Combined Aerobic and Resistance Exercise
- Where
- 2 sites in Norway, Sweden
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Norwegian School of Sport Sciences
Breast Cancer
Large Segmentation Radiotherapy ± Deep Inspiration Breath Hold(DIBH) for Left Breast Cancer
The study is a single-center, prospective, non-randomized controlled study. The primary objective is to examine the clinical outcomes of utilizing Deep Inspiration Breath Hold (DIBH) in conjunction with hypo-fractionated…
- Trial name
- DLLEB (NCT06660628)
- Testing
- Large Segmentation Radiotherapy, DIBH, Surface guided radiation therapy
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Peking Union Medical College Hospital
Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
Breast cancer is one of the world's most common cancers in females. Most of the chemotherapy protocols used to treat breast cancer involve doxorubicin. Doxorubicin has a very significant antitumor effect on breast tumors.
- Conditions
- Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy, Doxorubicin, Doxorubicin Adverse Reaction
- Trial name
- NICBREASTRCT (NCT07897409)
- Testing
- Nicorandil Oral Tablet, Adriamycin (Doxorubicin)
- Where
- Egypt
- Volunteers
- 146 people
- Sponsor
- Universiti Sains Malaysia
Breast Cancer
Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients
The purpose of this study is to investigate whether cells from a biopsy taken from the patient skin can be transformed into cardiomyocytes the changes in cardiomyocyte (heart muscle cells) when grown in a special culture medium…
- Trial name
- NCT02772367
- Testing
- skin punch biopsy
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms
Determinants of Physical Activity Level in Pediatric Oncological Patients Treated With Cardiotoxic Therapy - a Study Protocol
Cancer treatment in children is generally effective, but unfortunately, it often comes with side effects-unwanted negative impacts.
- Trial name
- NCT06256068
- Volunteers
- 300 people
- Sponsor
- Medical University of Warsaw
Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma
RElugolix VErsus LeUprolide Cardiac Trial
This clinical trial investigates the impact of prostate cancer treatment, specifically androgen deprivation therapy (ADT), on the heart and coronary vessels among men with localized, non-metastatic prostate cancer undergoing…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- REVELUTION (NCT05320406)
- Testing
- Radiation therapy, Leuprolide, Relugolix
- Where
- 4 sites in United States
- Volunteers
- 94 people
- Sponsor
- Emory University
Doxorubicin Induced Cardiomyopathy, Breast Cancer
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity
This is a randomized controlled clinical trial that aims to evaluate the safety and efficacy of Dapagliflozin as a cardioprotective in doxorubicin-induced cardiotoxicity in breast cancer patients.
- Trial name
- NCT06427226
- Testing
- Dapagliflozin 10mg Tab
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Tanta University
Leukemia, Hodgkin Disease
Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia
The research proposal focuses on evaluating the efficacy of atorvastatin in reducing cardiotoxicity caused by anthracycline chemotherapy in patients with hematologic malignancies, specifically acute myeloid leukemia (AML) and…
- Trial name
- NCT06684509
- Testing
- Atrovastain
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Assiut University
Breast Neoplasms
Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B
In the context of breast cancer, in case of an indication for chemotherapy, anthracycline-based protocols make it possible to improve the overall survival of patients most at risk.
- Trial name
- SCARA-B (NCT06443645)
- Testing
- Anthracycline
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Paul Strauss
Neoplasm, Breast, Heart Failure
Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
Rationale: In addition to surgery, effective breast cancer (BC) treatment typically requires chemotherapy, radiotherapy, or both.
- Conditions
- Neoplasm, Breast, Heart Failure, Cardiotoxicity, Ventricular Dysfunction
- Trial name
- BLOC-II (NCT05851053)
- Testing
- Echocardiography
- Where
- Netherlands
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen